Search bioRxiv⌕ Search

Biology subjects

Forrest, W.

Publications and source records attributed to Forrest, W..

2 recordsLinked to original sources

Fishash: A contingency table approach to Perturb-seq guide assignment

BackgroundSingle-cell pooled CRISPR screens (Perturb-seq) are a powerful tool in functional genomics. A key preprocessing step is to determine which cells received which perturbations based on possibly noisy sequencing counts of the guide RNA library. Many existing approaches to this problem require fitting probabilistic models which may be computationally expensive on large screens with 10s of thousands of cells and guides. ResultsWe propose to view the guide count matrix as a contingency table and use Fishers Exact Test to test for associations between cell and guide barcodes. This approach is fast, normalizes for both cell and guide-specific size factors, and provides a p-value for each cell-guide pair. Our method further uses a multiple testing correction approach that accounts for the correlation structure between the tests, and a correction for Simpsons paradox that arises due to hidden confounding. Additionally, to facilitate the development and benchmarking of guide assignment methods, we propose a framework for simulating guide counts with a realistic model of sequencing noise. ConclusionsWe find that our method compares favorably to existing methods in both accuracy and runtime on simulated and real datasets. We provide our method in an easy to use R package, fishash, available at https://github.com/jackkamm/fishash. Additionally, the code to reproduce the results of this manuscript is available at https://github.com/jackkamm/fishash_analysis.

genomics↗

RTK-dependent inducible degradation of mutant PI3K alpha drives GDC-0077 (Inavolisib) efficacy

PIK3CA is one of the most frequently mutated oncogenes; the p110 protein it encodes plays a central role in tumor cell proliferation and survival. Small molecule inhibitors targeting the PI3K p110 catalytic subunit have entered clinical trials, with early-phase GDC-0077 (Inavolisib) studies showing anti-tumor activity and a manageable safety profile in patients with PIK3CA-mutant, hormone receptor-positive breast cancer as a single agent or in combination therapy. Despite this, preclinical studies have shown that PI3K pathway inhibition releases negative feedback and activates receptor tyrosine kinase signaling, reengaging the pathway and attenuating drug activity. Here we discover that GDC-0077 and taselisib more potently inhibit mutant PI3K pathway signaling and cell viability through unique HER2-dependent degradation. Both are more effective than other PI3K inhibitors at maintaining prolonged pathway suppression, resulting in enhanced apoptosis and greater efficacy. This unique mechanism against mutant p110 reveals a new strategy for creating inhibitors that specifically target mutant tumors with selective degradation of the mutant oncoprotein and also provide a strong rationale for pursuing PI3K degraders in patients with HER2-positive breast cancer.

cancer biology↗